Phio Pharmaceuticals ((PHIO)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Phio Pharmaceuticals is conducting a clinical study titled ‘Dose Escalation Study of Neoadjuvant Intratumoral PH-762 for Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma’. The study aims to evaluate the safety and tolerability of PH-762, an RNAi molecule targeting PD-1, in treating specific skin cancers. This research is significant as it explores a novel treatment approach for these conditions.
The intervention being tested is PH-762, administered through intratumoral injections. This drug is designed to inhibit PD-1, potentially enhancing the immune response against tumors.
The study follows an interventional design with a single-group model. There is no masking involved, and the primary purpose is treatment. Participants will receive escalating doses of PH-762, with observations made between doses.
The study began on August 22, 2023, with an estimated primary completion date in 2025. The last update was submitted on July 28, 2025. These dates are crucial for tracking the study’s progress and potential data release.
This update could influence Phio Pharmaceuticals’ stock performance positively, as successful results may enhance investor confidence. The study’s progress could also impact competitors in the oncology sector, prompting further interest in RNAi-based therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.